Cameron J Turtle - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Cameron J Turtle

Showing results (81-90 of 130) with videos related to

Pageof 13

Sort By:

Blood Advances|November 20, 2019

Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapyJoshua A Hill, Elizabeth M Krantz, Kevin A Hay, et al.

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 7, 2023

Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapyJoshua A Hill, Erika S Kiem, Atif Bhatti, et al.

Haematologica|July 2, 2026

A novel dose-dense strategy for CD19-directed CAR T-cell therapy is associated with durable responses without increased toxicity in patients with B-cell non-Hodgkin lymphomaValentín Ortiz-Maldonado, Emily C Liang, Jennifer J Huang, et al.

Blood|August 13, 2010

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptorMichael Hudecek, Thomas M Schmitt, Sivasubramanian Baskar, et al.

Blood Advances|September 29, 2023

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLLEmily C Liang, Aya Albittar, Jennifer J Huang, et al.

Blood Advances|October 25, 2019

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapyMazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.

Blood Advances|August 8, 2025

NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell LymphomaSairah Ahmed, John F DiPersio, James H Essell, et al.

Nature Communications|January 12, 2020

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapyAlyssa Sheih, Valentin Voillet, Laïla-Aïcha Hanafi, et al.

Journal for Immunotherapy of Cancer|November 18, 2025

Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARsErik L Kimble, Jocelyn H Wright, Aiko Torkelson, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021

Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid LeukemiaQuy Le, Sommer Castro, Thao Tang, et al.

Pageof 13

Search research articles

Showing results (81-90 of 130) with videos related to

Sort By:

Pageof 13

Blood Advances|November 20, 2019

Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapyJoshua A Hill, Elizabeth M Krantz, Kevin A Hay, et al.

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|February 7, 2023

Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapyJoshua A Hill, Erika S Kiem, Atif Bhatti, et al.

Haematologica|July 2, 2026

Blood|August 13, 2010

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptorMichael Hudecek, Thomas M Schmitt, Sivasubramanian Baskar, et al.

Blood Advances|September 29, 2023

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLLEmily C Liang, Aya Albittar, Jennifer J Huang, et al.

Blood Advances|October 25, 2019

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapyMazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.

Blood Advances|August 8, 2025

NKTR-255 Enhances Complete Response Following CD19 CAR-T in Patients with Relapsed/Refractory Large B-cell LymphomaSairah Ahmed, John F DiPersio, James H Essell, et al.

Nature Communications|January 12, 2020

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapyAlyssa Sheih, Valentin Voillet, Laïla-Aïcha Hanafi, et al.